Histone deacetylase inhibitors in cancer: What have we learned?

The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single‐agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 121; no. 8; pp. 1164 - 1167
Main Authors Whittle, James R., Desai, Jayesh
Format Journal Article
LanguageEnglish
Published United States 15.04.2015
Subjects
Antibiotics, Antineoplastic - administration & dosage
Benzofurans - administration & dosage
Doxorubicin - administration & dosage
Female
Histone Deacetylase Inhibitors - administration & dosage
Humans
Hydroxamic Acids - administration & dosage
Male
Sarcoma - drug therapy
Online AccessGet full text

Cover

More Information
Summary:The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single‐agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be the focus of future studies.
Bibliography:See referenced original article on pages
1223‐30
this issue.
SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.29177